Literature DB >> 9155547

Adverse effects and drug interactions of medications commonly used in the treatment of adult HIV positive patients: Part 2.

R Heylen1, R Miller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9155547      PMCID： PMC1195751          DOI： 10.1136/sti.73.1.5

Source DB:  PubMed          Journal:  Genitourin Med        ISSN： 0266-4348


× No keyword cloud information.
  10 in total

1.  Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.

Authors:  C Katlama; D Ingrand; C Loveday; N Clumeck; J Mallolas; S Staszewski; M Johnson; A M Hill; G Pearce; H McDade
Journal:  JAMA       Date:  1996-07-10       Impact factor: 56.272

Review 2.  Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA.

Authors:  C C Carpenter; M A Fischl; S M Hammer; M S Hirsch; D M Jacobsen; D A Katzenstein; J S Montaner; D D Richman; M S Sáag; R T Schooley; M A Thompson; S Vella; P G Yeni; P A Volberding
Journal:  JAMA       Date:  1996-07-10       Impact factor: 56.272

3.  Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.

Authors:  S Staszewski; C Loveday; J J Picazo; P Dellarnonica; P Skinhøj; M A Johnson; S A Danner; P R Harrigan; A M Hill; L Verity; H McDade
Journal:  JAMA       Date:  1996-07-10       Impact factor: 56.272

4.  Renal failure after treatment with ritonavir.

Authors:  M Duong; C Sgro; M Grappin; F Biron; A Boibieux
Journal:  Lancet       Date:  1996-09-07       Impact factor: 79.321

5.  A preliminary trial of lamivudine for chronic hepatitis B infection.

Authors:  J L Dienstag; R P Perrillo; E R Schiff; M Bartholomew; C Vicary; M Rubin
Journal:  N Engl J Med       Date:  1995-12-21       Impact factor: 91.245

6.  Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.

Authors:  J J Eron; S L Benoit; J Jemsek; R D MacArthur; J Santana; J B Quinn; D R Kuritzkes; M A Fallon; M Rubin
Journal:  N Engl J Med       Date:  1995-12-21       Impact factor: 91.245

7.  A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group.

Authors:  S A Danner; A Carr; J M Leonard; L M Lehman; F Gudiol; J Gonzales; A Raventos; R Rubio; E Bouza; V Pintado
Journal:  N Engl J Med       Date:  1995-12-07       Impact factor: 91.245

8.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.

Authors:  J H Condra; W A Schleif; O M Blahy; L J Gabryelski; D J Graham; J C Quintero; A Rhodes; H L Robbins; E Roth; M Shivaprakash
Journal:  Nature       Date:  1995-04-06       Impact factor: 49.962

9.  The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study.

Authors:  R van Leeuwen; J M Lange; E K Hussey; K H Donn; S T Hall; A J Harker; P Jonker; S A Danner
Journal:  AIDS       Date:  1992-12       Impact factor: 4.177

10.  Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.

Authors:  A C Collier; R W Coombs; D A Schoenfeld; R L Bassett; J Timpone; A Baruch; M Jones; K Facey; C Whitacre; V J McAuliffe; H M Friedman; T C Merigan; R C Reichman; C Hooper; L Corey
Journal:  N Engl J Med       Date:  1996-04-18       Impact factor: 91.245
  10 in total
  12 in total

1.  Drug points: severe ergotism associated with interaction between ritonavir and ergotamine.

Authors:  L Liaudet; T Buclin; C Jaccard; P Eckert
Journal:  BMJ       Date:  1999-03-20

2.  Hyperlactataemia and hepatic steatosis: mitochondrial toxicity of nucleoside reverse transcriptase inhibitors.

Authors:  D Pao; C Watson; B Peters; S B Lucas; R F Miller
Journal:  Sex Transm Infect       Date:  2001-10       Impact factor: 3.519

3.  Deafness caused by didanosine.

Authors:  M Vogeser; R Colebunders; K Depraetere; P Van Wanzeele; S Van Gehuchten
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-03       Impact factor: 3.267

4.  Reporting adverse drug reactions in HIV infection.

Authors:  P R Arlett; E H Lee; M Hooker; J H Darbyshire; A M Breckenridge
Journal:  Genitourin Med       Date:  1997-10

5.  Drug interactions of protease inhibitors.

Authors:  M Simmonds
Journal:  Genitourin Med       Date:  1997-06

Review 6.  Pharmacokinetic factors in the modern drug treatment of tuberculosis.

Authors:  J G Douglas; M J McLeod
Journal:  Clin Pharmacokinet       Date:  1999-08       Impact factor: 6.447

Review 7.  Drug interactions of HIV protease inhibitors.

Authors:  L I Malaty; J J Kuper
Journal:  Drug Saf       Date:  1999-02       Impact factor: 5.606

8.  Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Joint Tuberculosis Committee of the British Thoracic Society.

Authors: 
Journal:  Thorax       Date:  1998-07       Impact factor: 9.139

Review 9.  Prime Drug Interplay in Dental Practice.

Authors:  Sumedha Mohan; Vivek Govila; Ashish Saini; Sunil Chandra Verma
Journal:  J Clin Diagn Res       Date:  2016-03-01

Review 10.  Urologic complications of HIV and AIDS.

Authors:  Chris F Heyns; Adam E Groeneveld; Nelson B Sigarroa
Journal:  Nat Clin Pract Urol       Date:  2009-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.